EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)

Summary

GRWD0715 is an orally administered, selective inhibitor of the Endoplasmic Reticulum Aminopeptidase 1 \[ERAP1\] enzyme being explored as a potential new treatment for axial spondyloarthritis (axSpA), a long term condition caused by inflammation predominantly affecting the sacroiliac joints (SIJs) and spine.

Timeline

Start

2025-07-28

Primary completion

2028-04-30

Completion

2028-09-30

Drugs

Indications